Recently stock market analysts have updated their consensus ratings on shares of Affimed Therapeutics B.V. (AFMD). The latest broker reports which are currently outstanding on Monday 9th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

02/22/2016 – Affimed Therapeutics B.V. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 8 price target on the stock.

12/10/2015 – Laidlaw began new coverage on Affimed Therapeutics B.V. giving the company a “buy” rating. They now have a USD 15 price target on the stock.

12/03/2015 – Wells Fargo began new coverage on Affimed Therapeutics B.V. giving the company a “outperform” rating.

11/19/2015 – Affimed Therapeutics B.V. had its “outperform” rating reiterated by analysts at Oppenheimer. They now have a USD 19 price target on the stock.

10/15/2015 – Affimed Therapeutics B.V. had its “hold” rating reiterated by analysts at Jefferies. They now have a USD 7 price target on the stock.

04/22/2015 – Affimed Therapeutics B.V. had its “outperform” rating reiterated by analysts at BMO Capital Markets. They now have a USD 13 price target on the stock.

Affimed Therapeutics B.V. has a 50 day moving average of 4.11 and a 200 day moving average of 4.96. The stock’s market capitalization is 108.16M, it has a 52-week low of 2.76 and a 52-week high of 24.20.

The share price of the company (AFMD) was down -1.39% during the last trading session, with a high of 3.75 and the volume of Affimed Therapeutics B.V. shares traded was 169606.

View other investors thoughts on Affimed Therapeutics B.V. on our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.